EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY

BACKGROUND: International consensus and the 2021 WHO classification recognize eight molecular subtypes among Group 3/4 medulloblastoma (representing ~60% of tumors). However, very few clinical centers worldwide possess the technical capabilities to determine DNA-methylation patterns or other molecul...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Delaidelli, Alberto, Dunham, Christopher, Santi, Maria Rita, Negri, Gian Luca, Triscott, Joanna, Zheludkova, Olga, Golanov, Andrey, Ryzhova, Marina, Okonechnikov, Konstantin, Schrimpf, Daniel, Stichel, Damian, von Deimling, Andreas, Kool, Marcel, Pfister, Stefan, Ramaswamy, Vijay, Korshunov, Andrey, Taylor, Michael, Sorensen, Poul
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Embryonal Tumors
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168220/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noab090.039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados